Can Amgen's new-and-improved Kyprolis kick-start myeloma sales?

Can Amgen's new-and-improved Kyprolis kick-start myeloma sales?

Source: 
Fierce Pharma
snippet: 

Amgen multiple myeloma drug Kyprolis has struggled for years to live up to expectations, and competition's only getting fiercer. But the company is hoping a new, more convenient dosing regimen—backed by convincing data—will help do the trick.